AI Article Synopsis
- Invasive fungal infections, especially candidemia and invasive candidiasis, pose significant health risks, and the rise of drug-resistant fungal species creates a pressing need for new antifungal treatments.
- The review discusses in vitro studies on the pharmacokinetics and pharmacodynamics of new antifungal agents, highlighting key clinical studies on their safety and effectiveness.
- Rezafungin shows strong efficacy compared to other treatments, has a favorable safety profile, and allows for once-weekly dosing, making it a promising option for managing challenging fungal infections in outpatient settings.
Article Abstract
Introduction: Invasive fungal infections, especially candidemia and invasive candidiasis, continue to cause substantial morbidity and mortality. In addition, the emergence of drug-resistant species, notably and , along with limitations in available treatments, highlights the urgent need for novel, effective antifungal agents.
Areas Covered: This review discusses the results of in vitro studies evaluating the spectrum and highlights the pharmacokinetic/pharmacodynamic properties. It also includes discussions on two key clinical studies that assess safety, tolerability, and efficacy.
Expert Opinion: Rezafungin has demonstrated comparable efficacy to other echinocandins in two clinical studies and exhibits in vitro activity against a broad range of species and spp. It has a favorable safety profile with minimal side effects, and no drug interactions or effects on QT intervals. In contrast to other echinocandins, it demonstrates dose-dependent killing, a prolonged half-life, and low clearance make it suitable for once-weekly dosing, which is supported by clinical trials confirming its efficacy. Rezafungin offers a promising option for the outpatient management of difficult to treat fungal infections. It has become a valuable addition to the antifungal arsenal, with the potential to reduce hospital length of stay and hospitalization costs and combat drug-resistant species.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14656566.2024.2331775 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Invasive Candidiasis.
Infect Dis Clin North Am
December 2024
University of Alabama at Birmingham, 1900 University Boulevard, 223 THT, Birmingham, AL 35294, USA. Electronic address:
Invasive candidiasis (IC) is a term that refers to a group of infectious syndromes caused by a variety of Candida species, 6 of which cause the vast majority of cases globally. Candidemia is probably the most commonly recognized syndrome associated with IC; however, Candida species can cause invasive infection of any organ, especially visceral organs, vasculature, bones and joints, eyes, and central nervous system. The optimal use of these newer diagnostics coupled with a thoughtful clinical assessment of at-risk patients and the judicious use of effective antifungal therapy is a key to achieving good antifungal stewardship and improved patient outcomes.
View Article and Find Full Text PDFBiodetection Strategies for Selective Identification of Candidiasis.
Indian J Microbiol
December 2024
School of Health Sciences and Technology, UPES, Dehradun, Uttarakhand 248007 India.
Fungi are among the predominant pathogens seen in a greater proportion of infections acquired in healthcare settings. A common fungus that causes infections in medical settings is species. Hospitalized patients who suffer from fungal diseases such as candidiasis and candidemia often have elevated rates of mortality and morbidity.
View Article and Find Full Text PDF: A Tale of Stealth and Endurance.
ACS Infect Dis
December 2024
BRIC-Centre for DNA Fingerprinting and Diagnostics (CDFD), Hyderabad 500039, India.
() , an opportunistic human fungal pathogen, causes mucosal and deep-seated infections in immunocompromised individuals. Recently designated as a high-priority fungal pathogen by the World Health Organization (WHO), exhibits low inherent susceptibility to azole antifungals. In addition, about 10% clinical isolates of display co-resistance to both azole and echinocandin drugs.
View Article and Find Full Text PDFNew Perspectives on Antimicrobial Agents: Rezafungin.
Antimicrob Agents Chemother
December 2024
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Candidemia and invasive candidiasis persist as significant causes of morbidity and mortality. As fluconazole resistance rates rise, alternative means of treatment are necessary, either via mold-active azoles or extended durations of echinocandins. These come with the potential for undesirable side effects for triazoles or choosing between prolonged hospitalization or outpatient parenteral antimicrobial therapy in the case of echinocandins.
View Article and Find Full Text PDFMitochondrial targeting of SPFH proteins and requirement of stomatins for SDS-induced stress tolerance.
Microbiol Spectr
December 2024
Department of Sciences, John Jay College of the City University of New York, New York, New York, USA.
Article Synopsis
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!